CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

Haptoglobin Phenotype Is Associated With High-Density Lipoprotein–Bound Hemoglobin Content and Coronary Endothelial Dysfunction in Patients With Mild Nonobstructive Coronary Artery Disease Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction Complete Versus Culprit-Only Lesion Intervention in Patients With Acute Coronary Syndromes The Prognostic Significance of Periprocedural Infarction in the Era of Potent Antithrombotic Therapy: The PRAGUE-18 Substudy Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how? Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial Prognostic impact of non-culprit chronic total occlusions in infarct-related cardiogenic shock: results of the randomised IABP-SHOCK II trial Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study

Expert Opinion2021 Feb 16;105499.

JOURNAL:Pharmacol Res. Article Link

OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

M Banach, PE Penson, ACS EuroPath Central & South European Countries Project et al. Keywords: PCSK9 inhibitors; combination therapy; effectiveness; ezetimibe; safety; statins

Full Text PDF